<DOC>
	<DOCNO>NCT00160745</DOCNO>
	<brief_summary>The endothelium play important role regulation vascular tone regulation blood flow . Nitric oxide ( NO ) important know endothelium-derived vasodilating factor . Prospective study show hypercholesterolemia impairs endothelial function different vascular bed . Lowering total cholesterol particularly LDL-cholesterol statin lead improvement endothelium-dependent vasodilation forearm vasculature . There strong evidence suggest benefit merely related decrease cholesterol-levels . A recent study forearm vasculature demonstrate short-term lipid-lowering therapy improve endothelial function NO availability already 3 day lipid lowering therapy . Whether endothelial function renal vasculature hypercholesterolemic patient similarly influence yet address adequately . In present study investigate whether lipid lower therapy rosuvastatin alters renal endothelial function , assess systemic infusion NO synthase inhibitor L-NMMA , 3 42 day therapy .</brief_summary>
	<brief_title>Rosuvastatin Renal Endothelial Function</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Female male patient age 18 75 year fast LDL C concentration &gt; =160 &lt; 250mg/dl fast TG concentration = &lt; 350mg/dl History statin induce myopathy , serious hypersensitivity reaction HMGCoA reductase inhibitor ( statin ) . History hypersensitivity reaction inulin . Lipidlowering drug ( include lipid lower dietary supplement food additive ) within last 4 week . Diabetes mellitus , define glycosylated hemoglobin ( HbA1C ) upper limit normal ( ULN ) . Uncontrolled arterial hypertension ( &gt; 160/100mm Hg ) . Subjects consider unstable ( event within 12 week ) investigator follow event : myocardial infarction , unstable angina , myocardial revascularisation ( PTCA , CABG surgery another revascularisation procedure ) transient ischaemic attack ( TIA ) stroke . Significant arrythmias conduction disturbance . Congestive heart failure ( NYHA class III IV ) . Pregnant woman , woman breast feeding , woman childbearing potential use chemical mechanical contraception positive serum pregnancy test ( serum betahuman chorionic gonadotropin analysis ) . History homozygous familial hypercholesterolaemia know type III hyperlipoproteinemia ( familial dysbetalipoproteinemia ) . Use concomitant medication . Current active liver disease ( SGPT &gt; 2xULN ) severe hepatic impairment . Unexplained serum CK &gt; 3 time ULN ( e.g . due recent trauma , intramuscular injection , heavy exercise etc. ) . Serum creatinine &gt; 2,0 mg/dl creatinine clearance &lt; 80ml/min . History nephrolithiasis calcium oxalate aggregation . Uncontrolled hypothyroidism define thyroid stimulate hormone ( TSH ) &gt; 1,5 time UL subject whose thyroid replacement therapy initiate within last 3 month . Severe disorder gastrointestinal tract disease interfere pharmacodynamics pharmacokinetics study drug . History malignancy ( unless document diseasefree period exceed 10 year present ) exception basal cell squamous cell carcinoma skin . Women history cervical dysplasia would permit enter study provide 3 consecutive clear Papanicolaou ( Pap ) smear . History organ allograft . Serious unstable medical psychological condition , opinion investigator , would compromise subjectsÂ´s safety successful participation trial . Participation clinical study within 4 week precede treatment start . Past present alcohol drug abuse . Suspected confirm poor compliance . Previous enrolment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>endothelium , NO , renal , statin</keyword>
</DOC>